Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Bioequivalence of Sprinkle and Capsule Formulations of Lubiprostone, as Compared to Placebo

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Either has medically-confirmed diagnosis of chronic constipation (per Rome III), or meets the diagnosis as confirmed using the Rome III constipation module questionnaire during the Screening period.~* Is male or female, 18 or older years of age~* Should be on stable dose of fiber supplement or a concomitant medication for the indication of lowering blood pressure~Exclusion Criteria:~* Has any gastrointestinal (GI) condition, other than constipation, affecting GI motility or defecation~* Is unable to eat or drink, take oral medications, or to hold down oral medications due to vomiting

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lubiprostone Capsule (Type: ACTIVE_COMPARATOR): Lubiprostone 24 mcg capsule twice daily (BID) for 7 days.
- Lubiprostone Sprinkle (Type: EXPERIMENTAL): Lubiprostone 24 mcg sprinkle BID for 7 days.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo matching to lubiprostone (sprinkle/capsule) BID for 7 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).